Please login to the form below

Not currently logged in

Pfizer/BioNTech promote booster against Omicron

Preliminary laboratory studies suggest three doses of the Pfizer/BioNTech vaccine neutralises Omicron to the same extent as two doses neutralise the original, ‘wild-type’ SARS-CoV-2

Coronavirus vaccine

Serum antibodies induced by the Pfizer/BioNTech COVID-19 vaccine (BNT162b2, Comirnaty) neutralise the Omicron variant of SARS-CoV-2 after three doses, suggest preliminary laboratory studies.

The studies, announced by Pfizer/BioNTech, indicate that a third dose of their vaccine increases neutralising antibody titres 25-fold compared to two doses against the Omicron variant.

However, the companies stress that, because 80% of the virus spike protein is unaffected by Omicron’s mutations, ‘two doses may still induce protection against severe disease’.

“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Dr Ugur Sahin, CEO and co-founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season.”

However, Pfizer chairman and CEO Albert Bourla was more specific, stressing that three doses of the Pfizer/BioNTech vaccine “remains the best course of action to prevent the spread of COVID-19”.

The two companies added that work was progressing on an adapted vaccine to tackle Omicron, which could be available by March 2022.

“We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine,” said Dr Sahin.

Pfizer and BioNTech still expect to produce four billion doses of their vaccine next year, regardless of whether the original or adapted vaccine is required.

The Pfizer/BioNTech laboratory studies evaluated the effectiveness of their vaccine against Omicron by testing a panel of human immune sera obtained from the blood of those who had received two or three doses. Pseudovirus neutralisation tests assessed the levels of neutralising antibodies against both wild-type SARS-Cov-2 and Omicron spike proteins.

A third dose increased neutralising antibody titres against the Omicron strain spike by 25-fold, meaning that the neutralisation effects of three doses against the Omicron was comparable to that seen against the wild-type strain after two doses.

A third dose also strongly increased CD8+ T cell levels against multiple spike proteins including Omicron, which are believed to correlate with protection against severe disease.

Article by
Hugh Gosling

9th December 2021

From: Research



Subscribe to our email news alerts


Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...